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INTRODUCTION
Mesenchymal stem cells （MSCs） are multipotent 
precursor cells that differentiate into mesenchymal lin-
eages such as osteocytes, chondrocytes or adipo-
cytes1, 2）. MSCs also facilitate angiogenesis and wound 
healing through secretion of multiple growth factors 
and cytokines3, 4）. For historical reasons, bone marrow 
has been considered to be the best cell source for MSC 
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SUMMARY
In 2012, we established the Center for Regenerative Medicine in Dokkyo Medical University Hospital, and 
are now preparing the necessary equipment and preclinical evidence for cell therapy. Liposuction is a com-
monly used procedure in plastic surgery and the lipoaspirate is discarded as a medical waste. However, the 
lipoaspirate is known to contain abundant mesenchymal stem cells, and thus, it is currently one of the most 
feasible options of regenerative medicine. Several ongoing clinical trials of cell therapy （in Japan and over-
seas as well） are based on the CelutionTM system, an automated cell-processing machine utilizing lipoaspi-
rate. The merit of using such a machine is that collected cells are so abundant that it is not necessary to ex-
pand the cell number in a Cell Processing Center. Moreover, there are fewer risks of bacterial infection 
because the system is isolated from the ambient dust and operated automatically. Our group is now plan-
ning respective cell therapies for breast reconstruction after mastectomy, urinary incontinence and ischemic 
cardiovascular diseases, and all these protocols will be based on the CelutionTM system. Here, we report the 
initial test run of CelutionTM to confirm its safety and reproducibility.
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therapy1, 2）. However, bone marrow aspirate does not 
contain enough cells and the small amount of MSCs 
need to be expanded in cell culture. To clinically use 
bone marrow-derived MSCs, a Cell Processing Center 
（CPC） is required to expand the cell numbers. A CPC 
is also critical to prevent the bacterial contamination 
during expansion. Thus, securing sufficient MSCs is a 
key issue for clinical practice.
In the plastic or cosmetic surgery field, lipoaspirate 
is routinely discarded as a medical waste. The lipoaspi-
rate contains not only mature adipocytes, but also 
abundant stromal cells such as capillary endothelial 
cells and pericytes. The discovery of MSCs in fat tis-
sue provided the impetus for scientists to direct their 
attention to lipoaspirate, as an alternative MSC 
source5〜7）. Compared to bone marrow aspirate, li-
poaspirate contains sufficient number of MSCs and cell 
expansion by culture is not necessary.
From a clinical perspective, as much automation as 
possible is relevant as complicated procedures can lead 
to the risk of human error. In 2012, we established the 
Center for Regenerative Medicine in Dokkyo Medical 
University Hospital to promote regenerative therapy 
for breast reconstruction after mastectomy, urinary in-
continence and ischemic cardiovascular diseases as a 
multi-disciplinary project. Our primary goal is to make 
cell therapy available in our hospital. For that purpose, 
we chose autologous （derived from the same individu-
al） cell therapy using lipoaspirate as one of candidate 
strategies.
The CelutionTM system （Cytori Therapeutics Inc., 
San Diego, CA, USA） is an automated cell-processing 
machine, which originated from a team led by a plastic 
surgeon in California 5, 7）. The CelutionTM system effi-
ciently removes mature adipocytes from lipoaspirate 
and separates stromal cell fraction in the closed sys-
tem. Processing is complete within two hours, in which 
the stromal cells are isolated for same day transplanta-
tion subsequently in patients. However, in order to use 
this machine in subsequent cell therapy, strict adher-
ence to the guidelines is essential. In Japan, all the cell 
therapy protocols and the preclinical data must be 
submitted to and approved by the Ministry of Health, 
Labor and Welfare （Guidelines on clinical research us-
ing human stem cells, abbreviated in Japanese as HI-
TOKAN：http://www.mhlw.go.jp/bunya/kenkou/iry-
ousaisei.html）. It is especially important to ensure 
safety and reproducibility by using automated cell sep-
aration system. Here we carried out an initial test run 
using CelutionTM system and collected data for future 
submission to the Ministry of Health, Labor and Wel-
fare.
METHODS
Patient and Procedure
This project was approved by an ethical committee 
of Dokkyo Medical University Hospital. The informed 
consent to use lipoaspirate for research purpose was 
obtained from the patient. The patient was a 65 year-
old female. Previously her right breast was recon-
structed because of imbalance after mastectomy for 
breast cancer. This time residual subcutaneous fat in 
bilateral chest was removed by liposuction under gen-
eral anesthesia.
Test Run of CelutionTM System
We isolated adipose-derived stromal cells using the 
CelutionTM system. The process is as below. Briefly, 
the above lipoaspirate was washed by pre-warmed 
Ringer’s solution and digested by CelaseTM at room 
temperature. CelaseTM is an enzyme cocktail （including 
collagenase） that is optimized to degrade extracellular 
matrix. Mature adipocytes were subsequently re-
moved by centrifugation and stromal cell fraction was 
separated and washed. All of these procedures were 
done in closed container to be free from ambient dust.
Treatment of Adipose-Derived Stromal Cells
The residual red blood cells were hemolysed by in-
cubating with hypotonic solution （2.06 g/l Tris base, 
7.49 g/l ammonium chloride, pH 7.2） for 5 minutes at 
room temperature. After quenching by Hank’s buff-
ered salt solution （Life Technologies, Carsbad, CA, 
USA）, cell debris was removed by 100 mm cell strainer 
（BD Biosciences, Franklin Lakes, NJ, USA）. Number of 
live cells （unstained by trypan blue） was subsequently 
counted with hemocytometer. 
Contamination Check
Supernatant of collected cells was divided into three 
vials and contamination was checked. The absence of 
bacteria, fungi or mycoplasma was confirmed by re-
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spective culture test, level of endotoxin, and DNA.
Analysis of Cell Surface Antigen by Flow Cytometry
90％ of dispersed cells obtained were used for opti-
mization and flow cytometric analysis. Antibodies used 
were as follows：CD45-PerCP （BD Biosciences, 
#340953）, CD31-PE （Beckman Coulter, Brea, CA, 
USA, #IM2409）, CD34-FITC （BD, #348053）, CD90-
FITC （Beckman Coulter, #IM1839U）. Triple staining 
of PerCP, PE and FITC were done for each combina-
tion of antibodies and data were collected and ana-
lyzed by FACS Calibur and Cell Quest （BD Bioscienc-
es）.
Cell Culture and Differentiation Assay
The remaining 10％ of dispersed cells were cultured 
in standard cell culture condition （37°C, 5％ CO2, ad-
vanced DMEM-F-12 , 5％ fetal bovine serum, Life 
Technologies）. Cells were divided into two groups：
floating cells （e.g. leukocytes） and adherent cells. The 
group of adherent cells consisted of endothelial cells 
and mesenchymal stem cells but the endothelial cells 
barely proliferate and are eliminated by serial passag-
es （subculture of a small portion in a new dish）6）. Af-
ter two passages, cells were split into three different 
dishes：the dish for long time culture, that for osteo-
blast differentiation assay, and that for adipocyte dif-
ferentiation assay. In the long time culture, cells were 
maintained to be kept quiescent under the contact in-
hibition and culture medium was replaced （5％ serum） 
twice a week. In the differentiation assays, mediums 
were prepared separately in each of differentiation 
conditions for osteoblast and adipocyte, and the medi-
um was replaced twice a week. The constituents of 
each medium were advanced DMEM/F-12 （5％ se-
rum or serum free）, 100 nM dexamethasone, 10 mM 
b-glycerophosphat and 0.05 mM ascorbic acid-2-phos-
phate （Sigma-Aldrich, St. Louis, MO, USA） for osteo-
cyte differentiation, and advanced DMEM/F-12 （se-
rum-free）, 500 nM 1-methyl-3-isobutylxanthine, 1 mM 
dexamethasone, 10 mg/ml insulin, 100 mM indometha-
cin for adipocyte differentiation6）. Three weeks after 
differentiation assay process, cells were fixed by 10％ 
formaldehyde, and osteocyte calcification and lipid 
droplets were stained using alizarin red and oil red 
staining solution （Wako Pure Chemical, Osaka, Japan）, 
respectively. For a positive control of osteoblast differ-
entiation, non-transformed human fibroblasts （OUMS-
36 , #JCRB1006 .0） purchased from JCRB cell bank 
（Osaka, Japan） were used.
RESULTS
Operation of CelutionTM System
Disposable canister and tubes were properly con-
nected to the CelutionTM system machine and the li-
poaspirate was successfully poured into the canister. 
The machine automatically washed the tissue and 
weighed the amount. The starting weight of the sub-
cutaneous fat was 330 g. Then the machine enzymati-
cally digested extracellular matrix, following the re-
moval of mature adipocytes by centrifugation. 
Collected cells are known to be adipose-derived strom-
al cells, or coined as Adipose-Derived Regenerative 
Cells （ADRCs）. ADRCs were a mixture of various 
kinds of cells such as lymphocytes, endothelial cells or 
mesenchymal stem cells. Clinically ADRCs are known 
to be ready for transplantation to the patient but this 
time all of the cells were used for subsequent quality 
check.
Bacterial Contamination
Before collecting the ADRCs, supernatant of Ring-
er’s solution was poured into three vials. From these 
supernatant vials for bacterial, fungus or mycoplasma 
contamination check, there was no evidence of con-
tamination of these organisms, resulting in the recon-
firmation of the previous results in other facilities.
Dispersion of ADRCs and Live Cell Counting
After removal of residual red blood cells by hemoly-
sis, the number of mononuclear live cells was around 
1.5×107.
Analysis of Cell Surface Antigen by Flow Cytometry
We analyzed the following cell surface antigens for 
the collected ADRCs：CD45；a marker of leukocytes, 
CD31；a marker of endothelial cells, CD34；a marker 
of various progenitor cells including adipose precursor 
cells, and endothelial and smooth muscle precursor 
cells and CD90；a marker of MSCs. According to the 
literature, MSCs exist in CD45/CD31 double negative 
fraction6）. Moreover, at least in adipose tissue, cell sur-
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face CD34 and CD90 are mostly overlapping in 
MSCs8）. Therefore, we first gated cells with CD45 and 
CD31 and next analyzed the positivity of CD34 or 
CD90 in the limited fraction of CD45/CD31 double 
negative. As a result, 30 .1％ and 30 .4％ of total live 
cells were CD45−CD31−CD34＋ and CD45−CD31−
CD90＋, respectively （data not shown）. However, 53.8
％ was CD34 positive cells and 52.8 ％ was CD90 posi-
tive in the limited cells that belong in CD45/CD31 
double negative fraction （Figure 1）.
Cell Culture and Differentiation Assay
A portion of the collected ADRCs was expanded by 
cell culture assay. The ADRCs actively proliferated in 
standard culture condition but stopped under the con-
tact inhibition. Since the patient once had breast can-
cer, we investigated transformation of ADRCs into 
cancer cells in the long-term culture. As a result, no 
evidence of such a transformation was observed dur-
ing 160 days cell culture. In the culture with adipocyte 
differentiation condition, the ADRCs actively differenti-
ated into adipocytes that displayed massive synthesis 
of lipid droplets. In addition, in the appropriate culture 
condition, ADRCs differentiated into calcified osteo-
cytes （Figure 2a）. Osteoblast differentiation of ADRCs, 
however, was dependent of serum in the culture medi-
um. Without serum, ADRCs very rarely differentiated 
into osteocytes and instead, lipid droplets were synthe-
sized even in the presence of the osteoblast differentia-
tion stimuli （data not shown）. As a positive control, 
human embryonic fibroblast OUMS-36 intensively cal-
cified in the culture with osteoblast differentiation, 
with or without the serum （Figure 2b and data not 
shown）. OUMS-36 did not synthesize lipid droplets in 
any culture conditions （Figure 2 d and data not 
shown）. These data indicate that ADRCs contain sub-
stantial amount of adipose progenitors and some cells 
have potential to differentiate into osteocytes.
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Figure 1　 Flow cytomeric analysis for ADRC typing by cell surface antigens. ADRCs 
were triple-stained by anti-CD45-PerCP （leukocytes marker）, anti-CD31-
PE （endothelial cell marker） and anti-CD34-FITC （adipose progenitor 
marker） or anti-CD90-FITC （mesenchymal stem cell marker）. CD45/CD31 
double negative fraction was gated （upper, light blue rectangles, the ratio 
among live cells is depicted as percentage） for CD34 and CD90 analyses. 
The ratio of CD34 positive （lower left） and CD90 positive （lower rght） cell 
were 53.8％ and 52.8％，respectively, in the CD45/CD31 double negative 
fraction. Dotted line in light green indicates isotype control signal. 
Test run of automated cell-processing machine
DISCUSSION
The current study reports our bench evaluation of 
the CelutionTM system, which prepares ADRCs in an 
automatic and closed system. We confirmed the ab-
sence of any bacterial contamination, consistent with 
the manufacturers reports （Cytori Therapeutics Inc.）. 
When we use cultured cells, such as inducible Pluripo-
tent Stem （iPS） cells or bone marrow derived stem 
cells, for regenerative medicine, a Cell Processing Cen-
ter is required to prevent bacterial contamination. Al-
though our hospital does not have such a facility, the 
same or a superior level of safety could be achieved 
when we use the CelutionTM system. We also con-
firmed that ADRCs have substantial numbers of CD34 
or CD90 positive cells. According to a report by Cytori 
Therapeutics, the ratio of CD34 positive cells/total live 
cells is around 38％9）. In our test run, the percentage 
was 30 .1 , suggesting that the result was within the 
range of individual difference. In addition, the ADRCs 
successfully differentiated into adipocytes and osteo-
cytes that displayed lipid droplets and calcification, re-
spectively. Of note, one of the minimal criteria of mes-
enchymal ‘stem’ cells is multipotency to differentiate 
into both osteocytes and adipocyte10 , 11）. In our case, 
however, the evidence is not enough to conclude that 
ADRCs contain authentic ‘stem’ cells. For example, 
heterogeneous ADRCs might contain mutually exclu-
sive adipocyte progenitor and osteoblast. Nevertheless, 
from the clinical perspective, the potency of ADRCs 
（even though they might not be genuine ‘stem’ cells） 
to secrete multiple growth factors and cytokines seems 
very interesting. Since the efficacy of ADRCs depends 
on such secretory function, rather than differentiation 
potency per se 3, 4）, we are now preparing a measure-
ment of various growth factors and cytokines secreted 
in the culture medium, using a multiple biomarker as-
say system （Luminex microbeads array system, Lu-
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Figure 2　 Osteoblast and adipocyte differentiation assay. Cultured ADRCs and human 
embryonic fibroblasts OUMS-36 was stimulated for osteoblast （a , b） or 
adipocyte （c, d） differentiation. Calcification of osteocytes and lipid droplets 
were visualized with alizarin red （a , b） and oil red （c , d） staining, 
respectively. ADRCs actively differentiated into adipocytes that displayed 
massive synthesis of lipid droplets （c）. Although less intense than positive 
control, ADRCs differentiated into calcified osteocytes （a）. OUMS-36 calcified 
in the culture with osteoblast differentiation, even in the absence of serum （b）. 
The OUMS-36 could not differentiate into adipocytes （d）. Scale bars：200 mm.
Ken-ichi Inoue
minex Corporation, Austin, TX, USA）. 
Overall, our data of initial test run of the CelutionTM 
system indicate that using lipoaspirate and this system 
is a feasible option for cell therapy in terms of safety 
and reproducibility.
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